Table 2- Baseline demographic, clinical, surgical and laboratory information of patients with positive COVID-19 undergoing cardiovascular surgery based on survival status Table 2- Baseline demographic, clinical, surgical and laboratory information of patients with positive COVID-19 undergoing cardiovascular surgery based on survival status Table 2- Baseline demographic, clinical, surgical and laboratory information of patients with positive COVID-19 undergoing cardiovascular surgery based on survival status Table 2- Baseline demographic, clinical, surgical and laboratory information of patients with positive COVID-19 undergoing cardiovascular surgery based on survival status
Survived (n=58) Expired (n=6) Total (n=64)
Age 60.7 (14.18) 64.5 (9.91) 61.1 (13.82)
Gender (male) 44 (75.9) 4 (66.7) 48 (75)
DM 16 (27.6) 4 (66.7) 20 (31.3))
HTN 25 (43.1) 4 (66.7) 29 (45.3)
HLP 21 (36.2) 3 (50) 24 (37.5)
FH 2 (13.3) 0 (0) 2 (10.5)
Smoking 16 (27.6) 1 (16.7) 17 (26.6)
Opium 0 (0) 10 (17.2) 10 (15.6)
HF 23 (39.6) 2 (33.3) 25 (39)
Hx of MI 5 (8.6) 1 (16.7) 6 (9.4)
Hx of PCI 9 (15.5) 0 (0) 9 (14.1)
Hx of CABG 4 (6.9) 2 (33.3) 6 (9.4)
Surgery type
CABG 34 (58.6) 5 (83.3) 39 (60.9)
Valve 1 (1.7) 1 (16.7) 2 (3.1)
CABG + Valve 8 (13.8) 0 (0) 8 (12.5)
CABG + Other 1 (1.7) 0 (0) 1 (!.6)
Valve + Other 9 (15.5) 0 (0) 9 (14.1)
CABG + Valve + Other 2 (3.4) 0 (0) 2 (3.1)
Other 3 (5.2) 0 (0) 3 (4.7)
Symptom
Fever 54 (93.1) 4 (66.6) 58 (90.6)
Chills 4 (6.8) 2 (33.3) 6 (9.3)
Chest pain 28 (48.3) 3 (50) 31 (48.4)
Dry cough 27 (46.7) 3 (50) 30 (46.8)
Respiratory distress 18 (31) 1 (16.7) 19 (29.6)
LVEF (%) 44 (10.02) 43 (16.26) 44.5 (10.09)
WBC count (/µL) 11.11×103 (10.00-14.00) 13.66 ×103 (10.90-22.18) 11.11×103 (10.00-15.00)
Lymphocyte (%) 17.0 (13.66-22.20) 13.2 (9.11-15.15) 15.3 (11.84-21.00)
CRP (mg/L) 5.6 (3.72-9.00) 15.3 (3.03-29.96) 5.6 (3.72-11.76)
Data are shown as number (percent), mean (SD) or median (25th-75th IQR) CABG; Coronary artery bypass graft, CRP; C-reactive protein, DM; Diabetes mellitus, EF; Ejection fraction, FH; Family history of coronary artery disease, HF; Heart failure, HLP; Hyperlipidemia, HTN; Hypertension, Hx; History, LVEF; left ventricular ejection fraction, PCI; Percutaneous coronary intervention, WBC; white blood cell Data are shown as number (percent), mean (SD) or median (25th-75th IQR) CABG; Coronary artery bypass graft, CRP; C-reactive protein, DM; Diabetes mellitus, EF; Ejection fraction, FH; Family history of coronary artery disease, HF; Heart failure, HLP; Hyperlipidemia, HTN; Hypertension, Hx; History, LVEF; left ventricular ejection fraction, PCI; Percutaneous coronary intervention, WBC; white blood cell Data are shown as number (percent), mean (SD) or median (25th-75th IQR) CABG; Coronary artery bypass graft, CRP; C-reactive protein, DM; Diabetes mellitus, EF; Ejection fraction, FH; Family history of coronary artery disease, HF; Heart failure, HLP; Hyperlipidemia, HTN; Hypertension, Hx; History, LVEF; left ventricular ejection fraction, PCI; Percutaneous coronary intervention, WBC; white blood cell Data are shown as number (percent), mean (SD) or median (25th-75th IQR) CABG; Coronary artery bypass graft, CRP; C-reactive protein, DM; Diabetes mellitus, EF; Ejection fraction, FH; Family history of coronary artery disease, HF; Heart failure, HLP; Hyperlipidemia, HTN; Hypertension, Hx; History, LVEF; left ventricular ejection fraction, PCI; Percutaneous coronary intervention, WBC; white blood cell